Last reviewed · How we verify

NCT03414840: ACROSS

Assessment of Change in Atherosclerotic Plaque by Serial CCTA

Status unknown Last updated 29 June 2018
What this trial tests

trial testing Atorvastatin in Coronary Artery Disease in 400 participants. Status unknown.

Timeline
1 April 2018
Primary endpoint
28 February 2020
31 October 2020

Quick facts

Lead sponsorYonsei University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment400
Start date1 April 2018
Primary completion28 February 2020
Estimated completion31 October 2020
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Yonsei University

Who can join

19 and older, any sex, with Coronary Artery Disease or Hydroxymethylglutaryl-CoA Reductase Inhibitors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessment of Change in AtheROSclerotic Plaque by Serial CCTA (ACROSS) is designed as a prospective observational study which aim is to demonstrate the effect of statins on coronary atherosclerosis, assessed by quantitative analysis of CCTA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Atorvastatin

Trials testing the same drug.

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Yonsei University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03414840.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing